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The introduction of highly active antiretroviral therapy (HAART) has been an important breakthrough in the treatment of HIV-1
infection and has also a powerful tool to upset the equilibrium of viral production and HIV-1 pathogenesis. Despite the advent
of potent combinations of this therapy, the long-lived HIV-1 reservoirs like cells from monocyte-macrophage lineage and resting
memoryCD4+Tcellswhichareestablishedearlyduringprimaryinfectionconstituteamajorobstacletoviruseradication.Further
HAART interruption leads to immediate rebound viremia from latent reservoirs. This paper focuses on the essentials of the mole-
cular mechanisms for the establishment of HIV-1 latency with special concern to present and future possible treatment strategies
to completely purge and target viral persistence in the reservoirs.
1.Introduction
Infection with HIV-1, which was ﬁrst isolated in 1983, causes
AIDS, a syndrome that was ﬁrst reported in 1981 [1]. The
HIV-1 pandemic represents one of the great plagues in the
historyofmankindandamajorchallengeformedicine,pub-
lic health, and medical research [2]. The majority of people
living with HIV-1 belong to low- and middle-income coun-
tries.Forexample,sub-SaharanAfricaaccountsfortwothird
of all infected people with HIV-1, where in few countries
more than one in ﬁve adults are infected with HIV. South
and south East Asia have second highest number of people
living with HIV-1. Furthermore the epidemic is spreading
most rapidly in Eastern Europe and central Asia, where the
number of people living with HIV increased by 54.2% bet-
ween 2001 and 2009. UNAIDS estimated that 33.3 million
people were infected with HIV at the end 2009 compared to
26.2 million in 1999, a 27% increase in HIV infection. Each
year 2.6 million people are infected with HIV-1 and 1.8 mil-
lion die of AIDS (UNAIDS 2010). Much has been learned
about the science of AIDS and continuous research has
allowed the development of 25 diﬀerent active compounds
belonging to six diﬀerent drug families shifting the HIV-1
infection from a fatal illness into a chronic disease [3, 4].
HIV-1 life cycle can be categorized into two phases. The
early stage occurs between entry into host cells and integra-
tion into its genome (Figure 1). The late phase occurs from
the state of integrated provirus to full viral replication [5].
Similarly two types of viral latency can be diﬀerentiated:
preintegrationlatencyresultsingenerationofdiﬀerentforms
of viral DNA before integration, whereas postintegration
latencyreferstothelackofviralreplicationaftertheinsertion
ofviralDNAintohostgenome[6].Virusentersthroughsuc-
cessive interactions with CD4 and CXC chemokine receptor
type 4 (CXCR4) or CC chemokine receptor type 5 (CCR5);
as a consequence HIV-1 core (diploid single strand positive
sense RNA, tRNA primers, viral protease, retrotranscriptase,
and integrase) is released into cytoplasm [7, 8]. After reverse
transcription, the preintegration complex (linear dsDNA,
integrase, matrix protein, retrotranscriptase, viral protein r
and various host proteins) transportation into nucleus is
mediated by microtubule and dynein, thereby allowing the
infection of resting, nondividing cells. Linear dsDNA either
integratesintohostcellchromosomesorcirculartesasoneor
two long terminal repeat (LTR) containing circles [9, 10].
Activation of host cells induces the binding of tran-
scriptional preinitiation complex to enhancer elements in
the 5 LTR proximal promoter that gathers essential host2 Advances in Virology
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Figure 1: Schematic representation of HIV-1 life cycle and latency with current and possible targets for antiviral intervention. The HIV-1
life cycle begins with the attachment of virus to the receptor (CD4) and coreceptor (CXCR4 or CCR5), followed by fusion with target cell
membrane. After virus entry, the viral nucleocapsid enter the cytoplasm, undergoes reverse transcription and then uses cytoplasmic dynein
to move towards the nuclear pore complex. The preintegration complex is transported into nucleus through NPC, and then dscDNA either
circulizesasoneortwoLTRcontainingcircleorisintegratedintoahostcellchromosome.Afterintegrationtheprovirusremainsquiescentin
post integration latent state. On activation the viral genome is transcribed by cellular transcription factors, spliced mRNA are transported
into cytoplasm where viral mRNA translated into regulatory and structural viral proteins. New virions assemble and bud through cell mem-
brane, maturing through the activity of viral protease. The diﬀerent classes of antiretroviral drugs are available. Fusion or HIV co-receptor
inhibitors inhibit the entry of virions into a new target cell. The step of reverse transcriptase can be targeted, using nucleoside analogues or
non-nucleosidereversetranscriptaseinhibitors(NRTIandNNRTI,resp.).TheHIV-1integraseinhibitorsinhibitthestrandtransferreaction
intheintegrationprocess,acrucialstepinthestablemaintenanceoftheviralgenome,aswellaseﬃcientviralgeneexpressionandreplication.
The class of protease inhibitors interferes with the last stage of viral life cycle which results in the production of noninfectious viral particles.
The HIV maturation inhibitors disrupt a late step in HIV-1 Gag processing.
transcription factors, such as NF-κB, NFAT, AP-1 and SP1
which transmit activation signals to basal transcription
machinery and promote the binding of RNA polymerase II
to the TATA box to initiate transcription [11–13]. Transac-
tivation response element (TAR), a 59-nucleotide stem loop
structure, is then formed at 5  end of nascent viral transcript
that creates the binding site for viral transactivator (Tat)
which promotes eﬃcient elongation of viral transcripts
by recruiting the positive transcription elongation factor
b (PTEFb), thereby enhancing the functional capacity of
RNAPII [14]. Viral regulatory protein (Rev) regulates the
processing, nuclear cytoplasmic transport, and splicing of
HIV mRNA. HIV-1 large precursor proteins assemble to
create viable particles budding oﬀ the cell and are processed
into mature proteins [15].
In 1996, the introduction of highly active antiretroviral
therapy (a combination of three or more potent anti-HIV-1
drugs targeting diﬀerent steps of viral life cycle) has greatly
extended the survival and stabilized the AIDS pandemic on
global scale (Table 1). This therapy can reduce the plasma
virus levels below detection limits (<20 copies/mL) [16, 17].
However a residual viremia is still detected in patients on
HAART with very sensitive methods. Furthermore, HIV-1
reverts to measurable plasma level in less than two weeks
when HAART is interrupted [18]. These observations sug-
gestthatHAARTcannottotallyeliminateHIV.Thevirusper-
sistence in cellular reservoirs because of viral latency, cryptic
ongoing replication, or poor drug penetration represents the
major obstacles for its eradication [19].
HIV-1 replicates preferentially in activated CD4+ Tc e l l s
but these cells generally survive only for few days after infec-
tion. Hardly, an infected CD4+ lymphoblast survives long
enough to revert back to a resting memory state [20–22].
Furthermore, HIV-1 gene expression is largely suppressed asAdvances in Virology 3
Table 1: Licensed antiretroviral drugs.
Name Trade name Company Launched
Nucleoside/nucleotide reverse transcriptase inhibitors
Zidovudine Retrovir GlaxoSmithkline 1987
Didanosine Videx Bristol-Myers Squibb 1991
Zalcitabine HIVID Roche 1992
Stavudine Zerit Bristol-Myers Squibb 1995
Lamivudine Epivir GlaxoSmithkline/shire pharmaceuticals 1998
Abacavir Ziagen GlaxoSmithkline 1999
Tenofovir Viread Gilead 2001
Emtricitabine Emtriva Gilead 2003
Non-nucleoside reverse transcriptase inhibitors
Nevirapine Viramune Boehringer Ingelheim 1996
Efavirenz Sustiva, Stocrin Bristol-Myers Squibb, Merck 1998
Delavirdine Rescriptor Pharmacia, Upjohn, Agouron, Pﬁzer 1999
Rilpivirine Edurant Tibotec Therapeutics 2011
Etravirine Intelence Tibotec Therapeutics 2008
Protease inhibitors
Saquinavir Invirase Hoﬀmann-La Roche 1995
Indinavir Crixivan Merck 1996
Ritonavir Norvir Abbott, GlaxoSmithkline 1996
Nelﬁnavir Viracept Agouron, Pﬁzer 1997
Amprenavir Agenerase, Prozei Vertex 1999
Lopinavir + Ritonavir Kaletra, Aluvia Abbott 2000
Atazanavir Reyataz, Zrivada Bristol-Myers Squibb, Novartis 2003
Fosamprenavir Lexiva, Telzir Vertex, GlaxoSmithkline 2003
Tipranavir Aptivus Boehringer Ingelheim 2005
Darunavir Prezista Tibotec 2006
Entry inhibitors
Enfuvirtide Fuzeon Trimeris, Roche 2003
Maraviroc Celsentri, Selzentry Pﬁzer 2007
Integrase strand transfer inhibitors
Raltegravir Isentress Merck & Co., Inc. 2007
Multi-class combination inhibitors
Efavirenz, Emtricitabine, and
Tenofovir disoproxil fumarate Atripla Bristol-Myers Squibb and Gilead
Sciences 2006
Emtricitabine, Rilpivirine, and
Tenofovir disoproxil fumarate Complera Gilead Sciences 2011
cells undergo this transition because HIV-1 LTR transcrip-
tion is heavily dependent on the inducible host transcription
factors (NF-κB, NFAT, and AP-1, etc.) that are excluded from
the nuclei of resting cells [23, 24] .T h er e s u l ti sas t a b l y
integrated but transcriptionally silent provirus in a memory
T cell, whose function is to survive for longer period of
time. If the cell is activated by cytokine or other stimuli,
it can begin to produce virus; otherwise the virus persists
as integrated DNA, unaﬀected by antiretroviral drug [25].
Duringreboundviremia(whenHAARTwasinterrupted)the
virus could be detected from another reservoir (other than
resting CD4+ T cells) from peripheral blood monocytes,
dendritic cells, and macrophages in lymph node, can be
infected latently, and therefore contribute to the viral per-
sistence [26–28]. Furthermore several features make cells
from macrophages lineage potential HIV reservoir. The viral
particles produced in macrophages are budding into intra-
cytoplasmic compartments which may represent one of the
favored sites for HIV replication [29]. Furthermore cells
from macrophages lineage are also more resistant to apop-
tosis and cytopathic eﬀects, harbor virus for longer period of
time, and produce virus throughout their life span even in
the microglial brain cells [30].
HAART results in a four-phase decline of viremia [31]:
ﬁrst an initial rapid loss of virus due to clearance of infec-
ted activated CD4+ T cells surviving about one day because4 Advances in Virology
of viral cytopathic eﬀects or host cytolytic eﬀector mech-
anism; the second slower phase of viral decay in infected
macrophages, partially activated CD4+ T cells, and follicular
dendritic cells (FDCs) due to the clearance of several cell
population with a half-life of one to four weeks; the third
phase of decay corresponding to cells with half-life of
several weeks (memory cells); and the fourth phase with no
appreciable decline, caused by the activation of resting
memory CD4+ T cells [32]. During the fourth phase, HIV-1
p l a s m al e v e ln o r m a l l yr a n g e sf r o m1t o5c o p i e s( R N Ap e r
mL) and can be detected by extremely sensitive RT-PCR
assays [33].
A 60-year uninterrupted HAART has been estimated
beingnecessarytoeradicatethelatentreservoirs.Thelifelong
HAART treatment is today a necessary evil because of its
associationwithmanymetabolicdisordersandtoxicities[34,
35]. Moreover, its interruption leads to rapid viral rebound,
attributable to the persistence latently infected memory
CD4+ T cells. Cells from latently infected reservoirs (cell
whereviruspersistswithmorestablekineticsthanmainpool
of actively replicating virus) are immunologically alike from
uninfected cells and are insensitive to immune clearance and
HAART [36]. To address the persistence of transcriptionally
silent but replication competent HIV reservoirs, the ﬁrst
approach could be to strengthen and intensify HAART by
introducing new viral inhibitors. Secondly, if therapeutic
goal is virus eradication, then novel strategies need to be
adopted to target and clear the latent reservoirs by inducing
HIV-1replicationinlatentlyinfectedcells,whilemaintaining
or intensifying HAART in order to prevent spreading of new
infections [37].
2.MolecularInsightsintoHIV-1Latency
Two forms of viral latency have been seen on the basis whe-
ther or not HIV-1 genome has integrated into the host cell
genomes: preintegration and postintegration latency [38].
Preintegration latencyresultsin partial or complete blockade
of viral life cycle prior to integration of virus genome into
host genome. It could result from incomplete reverse tran-
scription or from restriction by factors such as APOBEC3G
(cellular deoxycytidinedeaminase whose function can be
counteracted by viral vif protein) [39, 40]. Further the prein-
tegrationlatencydoesnotappeartobeofclinicalsigniﬁcance
because unintegrated forms persist in the cytoplasm for only
one day and cannot account for long-term latently infec-
ted CD4+ T-cell reservoirs but this unintegrated form of
DNA remains stable for at least one month in nondividing
metabolically active macrophages [41, 42]. Postintegration
latency occurs when HIV-1 genome integrated into host
genome is reversibly silenced and is limited only by the life
span of the infected cells and its progeny. Most mechanisms
to maintain HIV-1 latency operate at transcriptional level.
2.1. The Site and Orientation of Integration. HIV-1 latency
mostly operates at the transcriptional level; for example,
the chromosome environment at the site of integration and
availability of viral and host factors can have inﬂuence on
viral latency [10]. HIV-1 integrates into the host chromoso-
mal DNA in nonrandom manner. Speciﬁc sequences at the
ends of dscDNA are required to target PIC predominantly
to the intronic regions of the actively transcribed genes [43].
One study of the integration sites in puriﬁed resting CD4+ T
cellsfromthepatientsonHAARTfoundmajorityofprovirus
(93%) located within the coding regions of host gene, prob-
ably owing to the increased chromatin accessibility of these
regions [44]. The ﬁnding that latent HIV-1 proviruses inte-
grate in actively transcribed regions may seem paradoxical
considering the establishment of transcriptional latent state
[45]. However, the viral replication from these proviruses
can suﬀer from intense transcriptional interference because
of the orientation of the proviruses or their proximity to a
stronger host gene promoter [46].
Thesterichindranceoccurs:whentheprovirusintegrates
inthesametranscriptionalorientationasthehostgene,read-
throughtranscriptionfromupstreampromoterdisplaceskey
transcription factors from HIV-1 promoter and prevents the
assembly of the preinitiation complex on the viral promoter,
thereby hindering HIV-1 transcription [47, 48]. These tran-
scriptional interferences could be reversed by inhibiting the
upstream transcription or by cooperatively activating viral
transcription initiation and elongation [49]. Furthermore,
integrated provirus suﬀering from transcriptional interfer-
ence becomes transcriptionally active following Tat expres-
sion, and this provirus can switch oﬀ the transcription of the
host genes within which it has integrated or can allow the
coexistence of expression of both host and viral genes [50].
Promoter occlusion occurs when provirus integrated in
oppositeorientationtothehostgenemayleadtothecollision
of two RNAPII complexes during elongation, which can lead
the premature termination of the transcription of one or
both complexes [45, 51]. Convergent transcription may also
allow for the elongation of both viral DNA strands which
results in the formation of double-stranded RNAs, might
lead to RNA-interference, RNA directed DNA methylation
or generation of antisense RNA [52, 53]. Furthermore, the
phenomenonofenhancertrappingcanoccurwhenenhancer
of one gene is placed out of context near the promoter of the
second gene. Taken together, the orientation-dependent reg-
ulation is highly variable and relies on the 5 LTR occupancy
and on the rate of host gene elongation [54, 55].
2.2. Availability of Host Cell Transcription Factors and HIV-1
Viral Proteins. HIV-1 gene expression is strongly dependent
on host cell transcription machinery and the lack of host
transcriptionalactivatororthepresenceofhosttranscription
repressors also inﬂuences the viral latency. The 5 LTR func-
tions as an HIV-1 promoter and contains several DNA
binding sites for various cellular transcription factors such
as SP1 and NF-κB which are required for viral replication,
whereas other sites, such as those binding NFAT, LEF-1,
COUP-TF,ets-1,USF,andAP-1,enhancetranscriptionwith-
out being indispensable [56–58]. The p50/p65 NF-κBh e t -
erodimer is sequestered into the cytoplasm in unstimulated
cells through its interaction with an inhibitory protein
of the family of NF-κB inhibitors (IκBs) [59]. Following
cellular activation, phosphorylation of IκBb yI κB kinaseAdvances in Virology 5
(IKK) results in its dissociation from NF-κB, NF-κBt r a n s -
locationintothenucleus,andtranscriptionofNF-κB-depen-
dent genes [60]. On the contrary, the NF-κB p50/p50 homo-
dimers, which lack the transactivation domain, recruit the
histone deacetylase HDAC-1 to the LTR, leading to local his-
tone deacetylation and to a repressive chromatin environ-
ment on the HIV-1 5 L T Ri nH I V - i n f e c t e dc e l l s[ 61, 62].
FollowingT-cellactivation,p50/p50 homodimersareuproo-
ted by the p50/p65 heterodimers, which recruit histone ace-
tyltransferases (CBP and p300) to enhance the viral replica-
tion [24, 63]. Furthermore, the p65 subunit of NF-κBs t i m -
ulates transcriptional elongation by interacting with RNAPII
complexes of cdk7/TFIIH and pTEFb which in turn phos-
phorylate the serine-5 and serine-2 residues, respectively,
in the carboxyl terminal domain (CTD) of RNAPII for the
eﬃcient transcription elongation [64, 65].
As far as NFAT is concerned, T-cell activation dephos-
phorylates cytoplasmic NFAT via PKC pathway and translo-
cates into the nucleus where it interacts with 5 LTR at the
sites overlapping the U3 NF-κB binding site and thus pro-
motes the chromatin remodeling by recruiting transcrip-
tional coactivator like CBP and p300 [66, 67]. Further the
AP-1 complex, composed of Jun, Fos, and ATF family mem-
bers, having three binding sites in HIV-1 5 LTR, cooperates
with NFAT to activate HIV-1 transcription through U3 NF-
κB/NFATbindingsites[68,69].Inadditiontohostcelltrans-
cription factors, HIV-1 transcription is boosted by viral pro-
tein like Tat [70]. Tat interacts with the cis-acting RNA
element TAR (transacitivation response element) present at
the 5  of viral transcripts. The inhibition of Tat also induces
latency because in its absence, transcription is initiated but
blocked at the promoter in the early stage of elongation due
totherepressivechromatinenvironment[71,72].Tatactivity
is regulated mainly through the acetylation of Lys28 and
Lys50 [73]. Tat acetylation by PCAF on Lys28 enhances the
recruitment of pTEF at 5  end of nascent viral transcripts
promoting eﬃcient elongation, whereas acetylation of Lys50
by CBP promotes the dissociation of Tat from Tat-cyclin T
complex, allowing its interaction with PCAF and Tat-PCAF
complex recruiting to the elongating RNAPII [74–76]. Some
cellular protein aﬀectstheacetylationstateofTatmodulating
i t sa c t i v i t y .S i r t u i n1 ,ac l a s sI I IH D A C ,a c t sa ss p e c i ﬁ cT a t
deacetylase, thus increasing the quantity of Tat that is avai-
lable to act as a transcriptional activator [77]. Further CDK9,
a component of pTEFb, is acetylated by hGCN5 and PCAF,
reducing the transcriptional activity of pTEFb and promot-
ing HIV-1 latency [78].
In addition to transcription factors and their regulators,
speciﬁc restriction factors exist to defend host cell against
retroviral infection. For example, APOBEC3G impairs early
phases of HIV-1 life cycle and may induce latency. APOB-
EC3G strongly inhibits HIV-1 replication in CD4+ T cells by
inducing C to U conversions in the viral strand DNA during
reverse transcription [79]. This viral replication inhibitory
eﬀect of APOBEC3G is only present in resting cells, where
it exists as an active, low molecular mass ribonuleoprotein
complex [80]. T-cell activation induces the shift from an
active low molecular mass to inactive high molecular mass
form of APOBEC3G that cannot restrict viral infection. This
inactive form of APOBEC3G can be found in tissue resident
na¨ ıveormemoryCD4+Tcells,whicharepermissivetoHIV-
1 infection [81].
2.3. The Chromatin Organization and Epigenetic Regulation
of HIV-1 Promoter. HIV-1 promoter activity depends on the
chromatin environment where two nucleosomes, namely,
nuc-0 and nuc-1, are precisely positioned at the viral pro-
moter in latently infected cell lines and impose a block to
transcriptional elongation. Nuc-1 nucleosome, located im-
mediately downstream the transcription initiation site,
impedes the LTR activity [82, 83]. Epigenetic modiﬁcation
and disruption of nucleosome, nuc-1, are required for LTR-
driven transcription activation and viral gene expression
[84].The chromatin organization can be modulated through
a variety of mechanisms, including posttranslational cova-
lent modiﬁcations of histone tails and ATP-dependent,
chromatin remodeling events [85, 86]. Histone modiﬁcation
(i.e., acetylation, methylation, phosphorylation, sumoyla-
tion,ADP-ribosylationandubiquitination)caninﬂuencethe
gene expressions, which are all reversible and localized to
N- and C-terminus of histone tails [87, 88]. Hypoacetyla-
tion of histones by histone deacetylase (HDACs) correlates
with transcription repression, whereas hyperacetylation by
histone acetyltransferase (HATs) induces the transcription
activation [89].
The silent proviral 5 LTR can be activated from postin-
tegration latency by cell treatment with a variety of stimuli,
including cytokines like TNF-α and IL-6, antibodies (anti-
CD3 and -CD28 stimulation) phorbol esters (PMA, PHA,
prostratin), or by viral proteins (Tat and Nef). The nucleo-
some nuc-1, located immediately downstream of transcrip-
tion start site, is speciﬁcally remodeled following IL-6, TNF,
or PMA treatment, and this event is speciﬁcally correlated
with the activation of HIV-1 gene expression [82, 84]. Fur-
thermore, HIV-1 transcriptional activation was shown to
occur following treatment with HDAC inhibitors (HDACIs)
such as trichostatin A (TSA), trapoxin (TPX), valproic acid
(VPA), and sodium butyrate (Na But), suggesting that dur-
ing latency nuc-1 is constitutively deacetylated by HDACs
[90, 91]. The HDACI-mediated transcriptional activation is
accompanied by speciﬁc remodeling of nuc-1 and by an
increased acetylation of H3K4 and H4K4 in the promoter
region [92].
Several transcription factors such as ying and yang (YY1)
and late SV40 factor (LSF; also known as TFCP2) repress the
HIV-1replicationbyrecruitingHDAC1torepressorcomplex
sequence located at position −10 to +27 nucleotides in
the LTR [93, 94]. Other host transcription factors, such as
AP-4 (activating protein-4), NF-κB p50/p50 homodimers,
and CBF-1 (C-promoter binding factor-1), can also recruit
HDACs to the LTR and inhibit viral transcription [61, 95].
By contrast viral proteins like Tat and several cytokines and
HDAC inhibitors decrease HDACs occupancy at the repres-
sor complex sequence and activate the transcription at 5 LTR
byrecruitingfactorswithHATactivitysuchasCREBbinding
protein (CBP), CBP-associated factors (PCAFs), and human
general control of amino acids synthesis protein 5, which
induces nucleosome hyperacetylation in cell lines [49, 96].6 Advances in Virology
Similarly, in the absence of Tat, LTR-associated nucleosomes
arehypoacetylated,andviralgeneexpressionissilenced,con-
tributing to viral latency. HDAC inhibitors are not sole fac-
tors to induce transcription; host factors such as NF-κB, NF-
AT, and SP-1 must also be recruited to the 5 LTR [97, 98].
Generally, the histone acetylation is associated with gene
activation while histone methylation can be associated with
both activation and silencing. For example, methylation of
histone 3 at lysine 4 and histone 3 at lysine 36 is found in
active genes whereas methylation of histone 3 at lysine 9 and
27 and histone 4 at lysine 20 is associated with gene silencing
[99]. The histone 3 at lysine 9 methylation that is medi-
ated by SUV39H1 (suppressor of variegation 3–9 homolo-
gue 1) has been correlated with heterochromatin assembly
by recruiting HP1Υ (heterochromatin protein 1 homologue-
gama), resulting in HIV-1 silencing [96]. The transcription
factor COUP-TF interacting protein 2 (CTIP2) plays an
essential role in promoting viral latency in microglial cells by
recruiting a chromatin modifying enzyme complex and by
establishing a heterochromatic environment at the HIV-1
promoter [100]. Actually, the CTIP2 recruits HDAC1, HD-
AC2, SUV39H1, and HP1 proteins to establish a hetero-
chromatic environment that leads to HIV-1 silencing in
severalcelllines[101].Finally,byalteringhistones,recruiting
other chromatin remodeling factors, and modifying the
activity of certain transcription factors, HDACs appear to be
critical for epigenetic repression of HIV-1 transcription and
for the maintenance of viral latency [102].
2.4.PosttranscriptionalLatencyandMicroRNAs. MiRNAsare
single-stranded noncoding RNAs of 19 to 25 nucleotides
in length that function as posttranscriptional regulator and
introduce a new level of complexity to virus-host interplay
[103, 104]. Further miRNAs can also regulate the gene exp-
ression at the epigenetic level by remodeling chromatin
surrounding [105]. Several cellular miRNAs (miR-28, miR-
125b, miR-150, miR-223, and miR-382) control HIV-1 rep-
lication by targeting all spliced or unspliced HIV-1 mRNA
except Nef coding mRNA [106]. These cellular miRNAs are
enriched in resting CD4+ T cells and inhibit the translation
of almost all HIV-1-encoded proteins contributing to viral
latency [107]. Furthermore, viral genome produces viral
interferences RNAs that can target the viral RNAs, cellular
mRNAs, and host miRNAs. By targeting its own mRNA,
HIV-1 induces its own latency [108, 109]. Moreover, HIV-1
can also suppress the miRNAs-mediated silencing pathway
by reducing the expression of miRNA-17, miRNA-5p, and
miRNA20a that results in increased expression of Tat cofac-
tor PCAF ultimately enhancing the viral transcription [110].
HIV-1 products interfere directly with the cellular RNAi
machinery through diﬀerent mechanisms. Firstly, Tat physi-
callyinteractswiththehelicasedomainofDicerandpartially
represses the ability of Dicer to process precursor dsRNA
intosmallinterferingRNAs(siRNAs)[111,112].Further,the
viral TAR sequence prevents the formation of a functional
RNA-induced silencing complex (RISC) by sequestering
the Dicer-interacting protein TAR RNA-binding protein 2
(TRBP2) [113]. Finally both cellular and and viral mRNAs
could be involved in maintaining HIV-1 latency or in con-
trolling low ongoing viral replication [114].
3.CellularReservoirsinHIV-1Pathogenesis
HIV-1 uses diﬀerent strategies to survive within infected
individuals. The macrophages, dendritic cells (DCs), and
CD4+ T lymphocytes are considered reservoirs for HIV-1
infection. In CD4+ T cells, the viral replication is dependent
upon the cell cycle of the host cell and HIV-1 entry into acti-
vated CD4+ T lymphocytes leads to productive infection.
Virionsfoundwithinmonocyte-derivedmacrophagespersist
and retain infectivity for weeks, thus providing an envi-
ronment for viral persistence. Dendritic cells capture and
internalize extracellular virions via DC-SIGN which can be
subsequently transmitted to T cells in trans. HIV-1 hidden
in DCs and macrophages certainly play an important role
for viral spread and cell-to-cell transmission, and its involve-
ment in long-term viral persistence will be discussed here.
3.1. Monocyte-Macrophage Lineage as Viral Reservoirs. Cells
of myeloid lineage including monocytes, macrophages, and
dendritic cells are the ﬁrst line of defense against pathogen-
esis, because these cells are critical immune cells responsible
for a wide range of both innate and adaptive immune func-
tions [28, 115]. These cells are important viral reservoirs and
responsible for the dissemination of HIV-1 into sanctuaries
such as brain.
Circulating monocytes are recruited to diﬀerent tis-
sues, diﬀerentiate into macrophages, and form the HIV-1
reservoirs. Furthermore, a minor monocyte subset, the
CD16+ is more permissive to infection than the more abun-
dant CD14+ CD16− monocytes subset, which account for
lessthan1%circulatingmonocytes[116].Macrophagescon-
tain the CD4 receptor and CCR5 and CXCR4 coreceptors
which are early cellular targets for HIV-1. These cells are able
toproduceandharborthevirusforlongerperiodoftimedue
to high resistance to cytopathic eﬀects [117]. The resident
macrophages of central nervous system like microglial cells
are involved in the pathogenesis of HIV-1-associated demen-
tia, survive for many years, and are potential reservoirs for
HIV-1 [118, 119].
Macrophages can harbor large quantities of unintegrated
viral DNA in circular form, which remains unstable for up to
twomonthsinnondividing macrophages[120,121].Further
the viral protein Vpr is important for viral replication in
monocyte macrophages lineage but not in nondividing
CD4+Tcells.ThedeletionofVprdecreasesthetranscription
from unintegrated HIV-1 DNA up to 10 times [122, 123]. A
recent ﬁnding shows that infected human macrophages can
supportpersistenttranscriptionfromthisunintegratedDNA
which suggests that these circular forms of episomal DNA
maythereforeaccountforpersistenceandexpressioninnon-
dividing cells such as macrophages [124, 125]. However, sev-
eral mechanisms generating HIV-1 postintegration latency
have been described in the macrophages, including lack of
functional Tat, availability of host transcription activator or
repressors, inﬂuence of chromatin environment, and host
a n t i v i r a lp r o c e s s e ss u c ha sm i R N A s[ 126].Advances in Virology 7
Anotherstrategythatallowsthevirustoinfectandpersist
in macrophages is the resistance to apoptosis. The NF-κB
pathwayisactivateduponHIV-1infectioninprimarymono-
cytes and macrophages [127, 128]. It has been proposed
that TNF-α-induced NF-κB activity might be involved in
the inhibition of apoptosis and the survival of monocytes
and macrophages. NF-κB-mediated resistance to TNF-α-in-
duced apoptosis might result in a decreased susceptibility to
apoptosis of macrophages versus T cells in the context of
chronic immune activation during HIV-1 infection [129].
Further, the absence of apoptosis in HIV-1-infected pri-
mary macrophages has been correlated with an increase in
antiapoptotic Bcl-2 and Bcl-XL proteins and a decrease of
proapoptotic Bax and Bad proteins [130]. Furthermore,
macrophages express 10 times lower number of cell surface
CD4 receptor than CD4+ T cells and therefore are less sus-
ceptibletoHIV-1superinfection[131].HighnumberofCD4
receptors in HIV-1-infected CD4+ T cells induce a dramatic
reduction in the infectivity of release virions by sequestering
the viral envelope by CD4, while the less number of CD4 on
the cell surface of the macrophages might favor the release
of infectious virions from infected cells and thereby could
optimize the transmission of virions to cells present in the
vicinity [132]. Further the viral life cycle of HIV-1 or virion
production is 6 times slower in MO than in primary T cells
due to a slower reverse transcription process, allowing the
MO to form long lasting viral reservoirs [133, 134].
Dendritic cells are also involved in HIV-1 propagation,
through capture of viruses by receptor DC-SIGN (DC-spe-
ciﬁc ICAM3-grabbing non integrin) as well as through eﬃ-
cient HIV-1 transmission to T cells at the virological synapse
[135]. Follicular dendritic cells in lymphoid tissues are spe-
cialized in trapping and retaining the antigens, including
HIV-1virions,ontheirsurfaceintheformsofimmunecom-
plexes [136, 137]. Further, mature myeloid dendritic cells
located in lymph nodes can sustain the very low virus rep-
lication and therefore have potential role in HIV-1 latency
[138].Themechanismofviralpersistenceinthesecellsisnot
yet clearly understood [139].
CD34+ haematopoetic cells (HPCs) also serve as a viral
reservoir, since a subpopulation of CD34+ HPCs expresses
CD4andCCR5and/orCXCR4andthesecellsaresusceptible
to HIV-1 infection [140, 141]. Furthermore, HIV-1-infected
CD34+ HPCs have been detected in some patients where
these HPCs are associated with impaired growth and devel-
opment [142]. Then these HPCs generate a subpopulation of
monocyte which diﬀerentiates in dendritic cells, generating
an infected cell lineage that may spread HIV-1 to sanctuaries
[143].
3.2. Lymphocytes: Source of Latently Infected Cells. The most
T lymphocytes in the body are in a resting G0 state, and
followingactivation,theserestingna¨ ıveTcells,inresponseto
antigen, undergo a burst of proliferation and diﬀerentiation
in response to antigen and give rise to eﬀector T cells. Most
of these cells die during the immune response, but a subset
survive and return to G0 state and become memory T cells.
These lymphocytes persist as memory cells with diﬀerent
pattern of gene expression for the long-term survival and
rapid response to the relevant antigen in the future [144,
145].
Indeed, the activated CD4+ T cells are highly susceptible
to HIV-1-infection and die quickly as a result of cytopathic
eﬀects either of the virus or of the host immune system.
However, a subset of HIV-1-infected CD4+ T cells revert
back to a resting state and survive for longer period of time
[38]. Both na¨ ıve and memory subpopulation of resting lym-
phocytes provide an extremely restrictive environment for
HIV-1 replication due to low CCR5 expression, low nucleo-
tide pools and ATP level, and cytoplasmic APOBEC3G [79,
146]. Sometime, viral DNA cannot produce viable particles
inthisenvironment,butitcangeneratesomeRNAtranscript
and produce HIV-1 Nef (negative factor) in resting CD4+ T
cells and macrophages that could increase cell activation and
facilitate viral replication, either in the same cell or in the
surrounding cells through production of soluble Nef from
HIV-1-infected macrophages [147, 148].
In addition to macrophages or dendritic cells, a stable
form of latency also occurs in CD4+ T cells that carry integ-
rated provirus [149]. Certain chemokines CCL19, CXCL9/
CXCL10, and CCL20 activate the coﬁlin and actin dynamics
necessary for the development of latency in resting CD4 T
cells [150]. Since the HIV-1 integration requires cell acti-
vation to allow eﬃcient reverse transcription and nuclear
import of preintegration complex [151], the postintegration
latency occurs when infected activated T cells return to
quiescentormemorycells.ThephenotypesoftheserestingT
cells carrying a nonproductive HIV-1 infection have speciﬁc
s e to fs u r f a c em a r k e r ss u c ha sC D 4 + ,C D 2 5 −, CD69−,a n d
HLA-DR− [152]. Further, it has been estimated to comprise
106–107cells in asymptomatic patients, whose infected na¨ ıve
CD4+ T cells can harbor an average of 3 to 4 copies of integ-
rated HIV-1 per cell [153]. These cells do not allow to comp-
lete viral replication unless they are activated, and their sta-
bility and long half-lives represent major obstacle to HIV-1
eradication [154].
4.TargetingHIV-1Reservoirs:ANew
Therapeutical Approach
The implementation of HAART therapy has improved the
survival and quality of life of HIV-1-infected individual, but
it has unable to eradicate the virus from latently infected
reservoirs like memory CD4+ T cells and macrophages con-
stituting a major obstacle in HIV-1 eradication [155]. The
frequencyof HIV-1-infected cells,in the patients on HAART,
has been reduced to less than one cell per 106 resting CD4
T cells, but after many years of treatment, the frequency
of these infected cells is not decreasing further [152, 156].
Moreover,somereservoirsarefoundintissuesanctuarysites,
like the brain, that are protected from drug penetration
[157].
Today, the current HIV-1 therapy has failed to demon-
strate signiﬁcant and persistent decline of these latent reser-
voirs, which appears small but stable and contains both wild
type and drug resistant viral species. These considerations
attract HIV-1 research to search for new and original anti
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HIV-1 latency fall into two keys: ﬁrst blocking the develop-
ment of latency and second reactivating the viral reservoirs
in chronically infected individuals to clear the virus. These
challenging targets could be achieved by targeting the viral
reservoirs by HAART intensiﬁcation or by using transcrip-
tional regulators.
4.1. HAART Intensiﬁcation. HIV-1 reservoirs are supposed
to cause persistent low levels of HIV-1 RNA at a few
copies/mL that are detected in HIV-1 patients on HAART.
HIV-1 RNA from these reservoirs results from ongoing low
level of viral replication conveying message to HIV-1 resear-
cher that HAART is not hard enough [158, 159]. To tackle
this problem, one possible solution is the HAART intensiﬁ-
cation. The objective of HAART intensiﬁcation is to achieve
complete suppression of residual viremia [160]. However,
recent data on HAART intensiﬁcation failed to decrease the
residual viremia any more than normal HAART, suggesting
that current regimen can halt ongoing cycles of viral replica-
tion eﬀectively [161]. The approval of potent drugs targeting
CCR5 and integrase (raltegravir) has raised the new hope
for successfully decreasing the reservoir size particularly in
patients with primary infection [162–164].
4.2. Strategies Based on Transcriptional Inhibitors to Control
HIV. Beside the combination of HIV-1 gp41, reverse trans-
criptase, and protease inhibitors, new drugs should be devel-
oped to target other steps of HIV-1 life cycle [165]. For
example proteins involved in the transcription of proviral
genome could be targeted. Further the drug could be desig-
ned to target cellular cofactors or viral protein like Tat that
involvesintheactivationoftranscription[166].Severaltran-
scription inhibitors already characterized such as C-termi-
nal truncated STAT5, Staf 50, prothymosin α, and thiore-
doxin reductase might be used to control the viral gene exp-
ression [167, 168]. In macrophages, the inhibition of NFAT
and 5 LTR interaction by siRNA suppress the HIV-1 replica-
tion and therefore progression of AIDS also [169]. Further-
more, the treatment of HIV-1-infected lymphocyte with O-
GlcNAcylation enhancing agent glucosamine represses viral
transcription thus opening the way to metabolic treatment
[170]. Further new approaches based on engineered tran-
scription factors are now emerging with zinc ﬁnger pro-
tein as an attractive therapy for HIV-1 since their binding
to HIV-1 LTR in a sequence-speciﬁc manner is associated
with repression of LTR activation [171, 172]. For exam-
ple, OKT18, a zinc ﬁnger protein, can reduce the HIV-1
replication by targeting the Tat-induced HIV-1 LTR activity.
Interesting, zinc-ﬁnger protein also has the ability to inﬂu-
ence the chromatin and nuclear organization through pro-
tein involved in epigenetic regulation [173, 174].
The HIV-1 proteins (Tat, Nef, gp 120) should be also tar-
geted, as these proteins have critical functions in diﬀerent
steps of viral life cycle and also in the acquired resistance to
apoptosis. A better understanding of mechanism involved in
resistance to apoptosis, has also allowed to devise new drugs
against host factors which render the cells susceptible to
die [175]. For example, the chemokine receptor CCR5,
involved in virus entry and apoptosis could be targeted
[176]. Further a chemotherapeutic drug, Imatibib, restored
apoptotic sensitivity of HIV-1 macrophages through inhi-
bition of activity of the prosurvival cytokine macrophages
colony stimulating factor [177]. Finally, the addition of
Akt inhibitors (Miltefosine) is also promising molecules for
targeting long-lived viral reservoirs [178].
4.3. HIV-1 Reactivation from Latent Reservoirs. A new strat-
egy so-called shock and kill has been recently proposed to
eradicatethevirusfrominfectedpatients.Themainobjective
istofacilitatethereactivationofvirusesfromthelatentreser-
voirs, naturally (via host immune system or viral cytopathic
eﬀects), which are then destroyed by HAART [16, 179].
Many factors have been involved in reactivation including
physiological stimuli, chemical compounds (phorbol esters),
HDACIs (histone deacetylase inhibitors), p-TEFb activators,
and activation with antibodies (anti-CD3). Several eradi-
cation protocols passed through preclinical studies but to
date all failed in clinical trials [180]. The combined therapy
with IL-2 and HAART has not reduced the HIV-1 reservoirs,
and viral rebound has been systematically observed. A com-
bination of antibodies (anti-CD3) and IL-2 has proved to
be highly toxic and is not further advised for HIV-1 treat-
ment [181]. In addition, IL-7 can reactivate HIV-1 from
latency in vitro through the induction of JAK/STAT signaling
pathways. IL-7 increases the TCR repertoire and induces
the proliferation of both na¨ ıve and memory T cells, mak-
ing this cytokine an attractive candidate for future study
[182].
The use of antibodies coupled to drugs and treatment
with immunotoxins are also proposed strategies for selective
killings of infected cells. The combination of immunotoxins
and viral reactivation agents has cleared HIV-1 in cultures
of lymphocyte from patients and also in animal model.
Unfortunately the toxic side eﬀects of this treatment pre-
cluded it for further development [183]. Furthermore,
HDAC inhibitors or DNA methylation inhibitors are an
attractive potential means of inducing broad reactivation
of HIV-1 reservoirs. The combination of TSA (an HDACI)
and TNF-α (NF-κB inducer) synergistically activates the
HIV-1 promoter. However, toxicity of these compounds un-
dermines their clinical interest for HIV-1 therapy [184].
Although promising results in the reduction of HIV-1 reser-
voirs were reported using HDAC inhibitor VPA (valproic
acid), more recent studies did not conﬁrm these results [185,
186]. However, the inability of VPA (a week HDACI) to reac-
tivate the latent reservoirs, when used alone, might have
impact on the decay of HIV-1 reservoirs, when combined
with other HIV-1 inducers (prostratin) [187]. Prostratin, a
nontumorigenicphorbolester,increasesHIV-1transcription
through PKC activation and induction of NF-κBa n dS P1 .
Prostratin also downregulates HIV-1 receptors, which has
the additional advantage of decreasing the risk of reinfection
[188]. This compound has been advanced in clinical devel-
opment, and recent synthesis made this drug available for
clinical trials [189].Advances in Virology 9
5. Conclusion
HIV-1 infection is currently controlled by HAART but it
has long-term toxicity and does not eradicate HIV-1 latent
reservoir. It is now increasingly clear that epigenetic restric-
tion poses an initial hurdle to viral transcription and cause
of maintenance of viral latency. HIV-1 latency is regulated
by both cellular and viral factors. A better understanding of
epigenetic regulation of HIV-1 latency and identiﬁcation of
new pharmacological targets would open the doors to clear
the viral reservoirs.
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